Page last updated: 2024-12-05

formestane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Formestane is a non-steroidal aromatase inhibitor. It is used to treat hormone-dependent breast cancer in postmenopausal women. It works by blocking the enzyme aromatase, which converts androgens (male hormones) into estrogens (female hormones). By reducing estrogen levels, formestane can slow the growth of breast cancer cells. Formestane is synthesized in a multi-step process that involves the use of various chemical reactions and reagents. It is studied because it may be a more potent and effective treatment option for some patients with breast cancer compared to other aromatase inhibitors. The research on formestane aims to understand its mechanism of action, efficacy, safety, and optimal dosage for treating breast cancer. '

Cross-References

ID SourceID
PubMed CID11273
CHEBI ID75172
SCHEMBL ID25717
MeSH IDM0063242

Synonyms (84)

Synonym
pub9t8t355 ,
unii-pub9t8t355
ccris 7483
cgp 32349
brn 1889793
androst-4-ene-3,17-dione, 4-hydroxy-
nsc 282175
formestane [inn:ban]
4-hydroxy-4-androstene-3,17-dione
4-hydroxy-delta(sub 4)-androstenedione
MLS002153359 ,
MLS001148070
NCI60_002316
4-oha
lentaron depot
smr000058722
cgp-32349
MLS000028826 ,
4-hydroxyandrost-4-ene-3,17-dione
4-hydroxyandrostenedione
formestane ,
savecream
lentaron
lentaron (tn)
formestane (inn)
D07260
b, aromatase inhibitor
androst-4-ene-3, 4-hydroxy-
nsc282175
nsc-282175
566-48-3
4-oh-a
formestane, solid
NCGC00164380-01
NCGC00164380-02
HMS2090I22
NCGC00015070-04
chebi:75172 ,
4-oh-androstene-3,17-dione
(8r,9s,10r,13s,14s)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione
(10r,13s)-4,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione
(8r,9s,10r,13s,14s)-10,13-dimethyl-4-oxidanyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione
A831133
tox21_302286
NCGC00255321-01
dtxcid1014113
cas-566-48-3
dtxsid3034113 ,
tox21_113509
tox21_112111
HMS2234J06
4-ohad
4-hydroxy-delta(4)-androstenedione
formestano
formestanum
lentaron(r)
17-dione
AKOS015895451
formestane [mi]
formestane [who-dd]
formestane [mart.]
formestane [inn]
S2208
DB08905
4-hydroxy-delta4-androstenedione
CCG-221077
HY-B0697
SCHEMBL25717
NCGC00344560-01
tox21_112111_1
AB00572625-07
OSVMTWJCGUFAOD-KZQROQTASA-N
(8r,9s,10r,13s,14s)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-quinone
OPERA_ID_865
SR-01000721948-2
sr-01000721948
lentaron(r)17-dione
cs333
bdbm225704
HMS3715G16
Q3077501
(8r,9s,10r,13s,14s)-4-hydroxy-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17(2h,6h)-dione
BCP03066
AS-75658

Research Excerpts

Overview

Formestane is an inhibitor of the aromatase enzyme which is uniquely responsible for the generation of estrone and estradiol from androgenic precursors. Formestane appears to be an effective, specific and well-tolerated aromatases inhibitor.

ExcerptReferenceRelevance
"Formestane is an inhibitor of the aromatase enzyme which is uniquely responsible for the generation of estrone and estradiol from androgenic precursors. "( [Effects of formestane on the skeletal system in ovariectomized and control rates].
Cegieła, U; Folwarczna, J; Janiec, W; Kaczmarczyk-Sedlak, I; Nowińska, B; Pytlik, M; Woźnica, H, 2003
)
2.14
"Formestane thus appears to be an effective, specific and well-tolerated aromatase inhibitor for the treatment of advanced postmenopausal breast cancer."( Formestane in the treatment of advanced postmenopausal breast cancer.
Höffken, K; Jonat, W; Possinger, K, 1994
)
2.45
"Formestane is a selective inhibitor of oestrogen synthesis by aromatase enzymes and induces disease regression in breast cancer patients. "( Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.
Bajetta, E; Bartoli, C; Buzzoni, R; Celio, L; Di Leo, A; Merson, M; Moglia, D; Noberasco, C; Sacchini, V; Zilembo, N, 1994
)
1.98
"Formestane is a new aromatase inhibitor used as second-line endocrine treatment for postmenopausal women with advanced breast cancer. "( Severe immune thrombocytopenia during formestane treatment.
Alonso, MC; Español, I; Muñíz-Díaz, E; Pujol-Moix, N, 1998
)
2.01

Effects

Formestane (4-OHA) has been proven to be highly effective with high systemic tolerability in treating ER. Adverse effects reported in approximately 13% of patients following intramuscular administration.

ExcerptReferenceRelevance
"Formestane (4-OHA) has been proven to be highly effective with high systemic tolerability in treating ER"( Dermal repeated dose toxicity study of the anti-breast cancer drug Formestane cream in Bama minipig.
Chen, Y; Gao, L; Huang, S; Li, H; Luo, Y; Teichmann, AT; Wu, Z; Zhang, L; Zou, L, 2023
)
2.59
"Formestane has been generally well tolerated in the relatively small clinical trials conducted to date with adverse effects reported in approximately 13% of patients following intramuscular administration."( Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
McTavish, D; Wiseman, LR, 1993
)
2.45
"Formestane has been studied in elderly patients with breast cancer and has been found to induce an overall response rate of 51% (95% CI, 35-67%)."( Steroidal aromatase inhibitors in elderly patients.
Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N, 2000
)
1.03

Treatment

Formestane pretreatment induced greater suppressions in brain NOx and GSH and elevations in brain MDA, as compared to vehicle treated CRS rats. Formestane treatment also decreased endogenous E(2) in female cortex and hippocampus, suggesting de novo synthesis selectively in these regions.

ExcerptReferenceRelevance
"Formestane pretreatment also induced greater suppressions in brain NOx and GSH and elevations in brain MDA, as compared to vehicle treated CRS rats."( Gender Based Differences in Stress-induced Gastric Ulcer Formation and its Regulation by Nitric Oxide (NO): An Experimental Study.
Chakraborti, A; Gulati, K; Ray, A, 2015
)
1.14
"Formestane treatment also decreased endogenous E(2) in female cortex and hippocampus, suggesting de novo synthesis selectively in these brain regions."( Brain estradiol content in newborn rats: sex differences, regional heterogeneity, and possible de novo synthesis by the female telencephalon.
Alt, JJ; Amateau, SK; McCarthy, MM; Stamps, CL, 2004
)
1.04
"Formestane-pretreated cells showed decreased sensitivity to killing by monocytes in the absence of Abs (mean = 45% cytolysis, P = .07) but significantly increased sensitivity to monocyte-mediated, antibody-dependent cellular cytotoxicity (MM-ADCC) (mean = 65%, P = .003)."( Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity.
Andrews, S; Braun, DP; Crist, KA; Parker, J; Shaheen, F; Staren, ED, 2005
)
1.05

Pharmacokinetics

ExcerptReferenceRelevance
" The formulated material achieved a significantly higher mean peak concentration (88% greater than that obtained using the unformulated powder) and a higher mean AUC (not significant)."( Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men.
Dowsett, M; Lloyd, P, 1990
)
0.28
" injection of 14C-formestane, the unchanged drug disappeared rapidly from plasma, the terminal elimination half-life being 18+/-2 min (N=3)."( Pharmacokinetics and metabolism of formestane in breast cancer patients.
Blum, W; Faigle, JW; Galli, B; Geisler, J; Gschwind, HP; Johannessen, DC; Kriemler, HP; Lønning, PE; Miller, WR; Schneider, W; Waldmeier, F; Winkler, T, 2001
)
0.92

Bioavailability

ExcerptReferenceRelevance
" The method has been validated for sensitivity, accuracy and precision and was found to be suitable for application to pharmacokinetic and bioavailability studies of peroral formulations of 4-OHA."( Determination of 4-hydroxyandrostenedione in plasma and urine by extractive alkylation and electron-capture gas chromatography.
Degen, PH; Schneider, W, 1991
)
0.28
"The choice of treatment for elderly breast cancer patients needs particular care because the presence of physiological functional impairments can modify the drug bioavailability in an unpredictable manner."( Steroidal aromatase inhibitors in elderly patients.
Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Dose-response curves were constructed for the aromatase inhibitor formestane and for herceptin. A 3-(4,5-dimethylthiazol)-2,.5-diphenyltetrazolium bromide assay was done for combined treatment. Further investigation of these 2 agents is necessary to confirm their relative efficacies.

ExcerptRelevanceReference
" These results confirm the dose-response relation previously established with plasma oestrogen measurements alone."( The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
Dowsett, M; Jacobs, S; Jones, AL; Lonning, PE; MacNeill, F; Powles, TJ, 1992
)
0.28
" These findings suggest a dose-response relationship between plasma oestrogen suppression at low postmenopausal levels and objective tumour response in breast cancer."( Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
Dowsett, M; Ekse, D; Jacobs, S; Johannessen, DC; Jones, A; Lønning, PE; McNeil, F; Powles, TJ, 1992
)
0.28
" Further investigation of these 2 agents, including the higher dosage of formestane (500mg), is necessary to confirm their relative efficacies."( Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Goa, KL; Wiseman, LR, 1996
)
1.97
" As expected, a dose-response stimulation of luciferase activity was observed in cells treated with estradiol."( Dehydroepiandrosterone stimulates the estrogen response element.
Bruder, JM; Oettel, M; Sobek, L, 1997
)
0.3
" Thus, use of a steroidal and a non-steroidal aromatase inhibitors in concert may be one way to improve breast cancer treatment and may also provide important information to a better understanding of the dose-response relationship between estrogen suppression and clinical effects."( Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Lønning, PE, 1998
)
0.56
" dosing confirmed a sustained release of formestane from the site of injection."( Pharmacokinetics and metabolism of formestane in breast cancer patients.
Blum, W; Faigle, JW; Galli, B; Geisler, J; Gschwind, HP; Johannessen, DC; Kriemler, HP; Lønning, PE; Miller, WR; Schneider, W; Waldmeier, F; Winkler, T, 2001
)
0.85
" Dose-response curves were constructed for the aromatase inhibitor formestane and for herceptin, and a 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide assay was done for combined treatment."( In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches.
Cavaliere, C; Ciardiello, F; Corvigno, S; Criniti, V; De Placido, S; Limite, G; Nardone, A; Picarelli, S; Tortora, G; Veneziani, BM, 2007
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 1.14.14.14 (aromatase) inhibitorAn EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor which interferes with the action of aromatase (EC 1.14.14.14) and so reduces production of estrogenic steroid hormones.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
17-oxo steroidAny oxo steroid carrying the oxo group at position 17.
hydroxy steroid
enolAlkenols; the term refers specifically to vinylic alcohols, which have the structure HOCR'=CR2. Enols are tautomeric with aldehydes (R' = H) or ketones (R' =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.30600.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency21.13600.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency24.28120.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency6.12520.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743053
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency61.13060.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency9.09450.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.09010.01237.983543.2770AID1645841
retinoid X nuclear receptor alphaHomo sapiens (human)Potency19.24900.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency58.00940.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency22.89430.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency62.63870.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.21950.000229.305416,493.5996AID588514; AID743069; AID743075; AID743077; AID743078; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency48.96620.001024.504861.6448AID743212
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency48.96620.023723.228263.5986AID743222
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.05180.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.33050.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency1.54840.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency24.54120.057821.109761.2679AID1159526
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency35.48130.010039.53711,122.0200AID588545
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency47.59640.000323.4451159.6830AID743065
tyrosine-protein kinase YesHomo sapiens (human)Potency38.70880.00005.018279.2586AID686947
gemininHomo sapiens (human)Potency20.59620.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency1.25890.125912.234435.4813AID1458
TAR DNA-binding protein 43Homo sapiens (human)Potency12.58931.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)58.60000.00011.753610.0000AID774132
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)58.60000.00002.015110.0000AID774132
AromataseHomo sapiens (human)IC50 (µMol)4.78280.00001.290410.0000AID1130100; AID1270810; AID1307751; AID1855795; AID255148; AID364069; AID436515; AID53576; AID53578; AID548357; AID672713; AID704989; AID774132
AromataseHomo sapiens (human)Ki0.14320.00000.60469.5010AID1270804; AID159833; AID53739; AID53878; AID54043
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)58.60000.00002.800510.0000AID774132
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AromataseHomo sapiens (human)Ks0.32400.10500.21400.3240AID159831
AromataseHomo sapiens (human)pIC501.37701.31001.34351.3770AID548357
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (64)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (197)

Assay IDTitleYearJournalArticle
AID1256778Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1412952Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2018MedChemComm, Jun-01, Volume: 9, Issue:6
Evaluation of A-ring fused pyridine d-modified androstane derivatives for antiproliferative and aldo-keto reductase 1C3 inhibitory activity.
AID1057277Cytotoxicity against ER-positive human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
AID1412951Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2018MedChemComm, Jun-01, Volume: 9, Issue:6
Evaluation of A-ring fused pyridine d-modified androstane derivatives for antiproliferative and aldo-keto reductase 1C3 inhibitory activity.
AID1256787Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID26668Half-life period of the compound1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and evaluation of a new series of mechanism-based aromatase inhibitors.
AID1256791Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at IC50 concentration after 48 hrs by flow cytometry (Rvb = 38.8%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID436515Inhibition of human placental aromatase assessed as conversion of [1-beta-3H]androstenedione to [1beta-3H]estrone after 20 mins by liquid scintillation counting2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors.
AID1256813Induction of apoptosis in human MDA-MB-231 cells assessed as effect on active-caspase-3 level after 72 hrs by western blotting2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1256808Induction of apoptosis in human MDA-MB-231 cells assessed as increase in cleaved PARP expression at IC50 concentration after 48 hrs by western blotting2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1256786Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1593297Inhibition of human placental microsome aromatase at 2 uM using [1beta3H]-androstenedione as substrate measured after 15 mins in presence of NADPH by liquid scintillation counting method relative to control2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
C-6α- vs C-7α-Substituted Steroidal Aromatase Inhibitors: Which Is Better? Synthesis, Biochemical Evaluation, Docking Studies, and Structure-Activity Relationships.
AID53578Inhibition of cytochrome P450 19A11992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and evaluation of a new series of mechanism-based aromatase inhibitors.
AID1299177Inhibition of human placental aromatase expressed in human MCF7 cells using [1beta-3H]-androstenedione as substrate at 1 uM after 1 hr by liquid scintillation counting method in presence of progesterone relative to control2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Exploring new chemical functionalities to improve aromatase inhibition of steroids.
AID1256812Induction of apoptosis in human MDA-MB-231 cells assessed as increase in caspase-3 precursor level after 72 hrs by western blotting2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1256798Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells after 48 hrs by Annexin-V/FITC staining based flow cytometry (Rvb = 5.4%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID548357Inhibition of human placental aromatase2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Molecular docking and QSAR study on steroidal compounds as aromatase inhibitors.
AID1693648Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1693647Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.
AID1057272Cytotoxicity against human MRC5 cells assessed as growth inhibition after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
AID1256803Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells after 72 hrs by Annexin-V/FITC staining based flow cytometry (Rvb = 2.76%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1130100Inhibition of human aromatase using androstenedione as substrate assessed as estrone formation at 10 uM after 30 mins by LC-MS/MS analysis2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Inhibitory effect of Rhus verniciflua Stokes extract on human aromatase activity; butin is its major bioactive component.
AID1193486Antiproliferative activity against human MRC5 cells assessed as inhibition of cell growth after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID1130099Inhibition of human aromatase using androstenedione as substrate assessed as remaining estrone level at 10 uM after 30 mins by LC-MS/MS analysis relative to control2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Inhibitory effect of Rhus verniciflua Stokes extract on human aromatase activity; butin is its major bioactive component.
AID667428Cytotoxicity against ER-negative human MDA-MB-231 cells after 1 hr by SRB assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives.
AID50906Inhibition of mouse constitutive androstane receptor (mCAR) activity at 10 uM was determined as percent remaining activity2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor.
AID23785Half life period was determined1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Mechanism and inhibition of cytochrome P-450 aromatase.
AID1256789Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at SubG1 phase at IC50 concentration after 48 hrs by flow cytometry (Rvb = 2.1%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID463562Inhibition of human recombinant aromatase at 0.6 uM2010Journal of natural products, Feb-26, Volume: 73, Issue:2
The taiwaniaquinoids: a review.
AID1193484Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID1256816Induction of apoptosis in human MDA-MB-231 cells assessed as degradation of cytoplasm after 48 and 72 hrs by giemsa staining based light microscopic analysis2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1693650Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.
AID1593299Inhibition of human placental microsome aromatase expressed in human MCF7 cells at 10 uM using [1beta3H]-androstenedione as substrate measured after 1 hr in presence of progesterone relative to control2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
C-6α- vs C-7α-Substituted Steroidal Aromatase Inhibitors: Which Is Better? Synthesis, Biochemical Evaluation, Docking Studies, and Structure-Activity Relationships.
AID1256785Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID159835Catalytic constant (Kcat) for reversible enzyme-ligand complex formation with human placental aromatase (PL2)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Interactions of thiol-containing androgens with human placental aromatase.
AID1193487Cell cycle arrest in human MCF7 cells assessed as cells accumulation at G0/G1 phase at IC50 concentration after 48 hrs by flow cytometry (Rvb = 47.55%)2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID1412953Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2018MedChemComm, Jun-01, Volume: 9, Issue:6
Evaluation of A-ring fused pyridine d-modified androstane derivatives for antiproliferative and aldo-keto reductase 1C3 inhibitory activity.
AID1192787Induction of apoptosis in human MDA-MB-231 cells at IC50 after 48 hrs by Giemsa staining-based light microscopy (Rvb = 7%)2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
AID1193490Cell cycle arrest in human MCF7 cells assessed as cells accumulation at subG1 phase at IC50 concentration after 48 hrs by flow cytometry (Rvb =1.83 %)2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID1256777Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1057276Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
AID255148Inhibitory concentration against aromatase protein from human placental microsomes using [1-beta-3H]-androstenedione; Competitive inhibition2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation.
AID53878Inhibition constant for human placental cytochrome P450 19A11992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and evaluation of a new series of mechanism-based aromatase inhibitors.
AID1256817Induction of apoptosis in human MDA-MB-231 cells assessed as formation of apoptotic bodies after 48 and 72 hrs by giemsa staining based light microscopic analysis2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1256790Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G0/G1 phase at IC50 concentration after 48 hrs by flow cytometry (Rvb = 51.6%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID53712Inhibition of Cytochrome P450 19A1 at the concentration of 0.25 uM1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and evaluation of 4-(substituted thio)-4-androstene-3,17-dione derivatives as potential aromatase inhibitors.
AID1256796Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2/M phase at IC50 concentration after 72 hrs by flow cytometry (Rvb = 10.4%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1193481Antiproliferative activity against ER positive human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID1855795Inhibition of aromatase in human breast tumor2022European journal of medicinal chemistry, Nov-05, Volume: 241An overview on Estrogen receptors signaling and its ligands in breast cancer.
AID1193480Antiproliferative activity against ER negative human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID159830Dithiothreitol (10 nM) reactivation of human placental aromatase following 1.0 uM inactivation for 5 minutes1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Interactions of thiol-containing androgens with human placental aromatase.
AID53716Inhibition of 1.25 uM [1-3H]-androst-4-ene-3,17-dione binding to Cytochrome P450 19A11984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Synthesis and evaluation of 19-aza- and 19-aminoandrostenedione analogues as potential aromatase inhibitors.
AID53715Inhibition of 0.25 uM [1-3H]-androst-4-ene-3,17-dione binding to Cytochrome P450 19A11984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Synthesis and evaluation of 19-aza- and 19-aminoandrostenedione analogues as potential aromatase inhibitors.
AID1256814Induction of apoptosis in human MDA-MB-231 cells assessed as nuclear condensation after 48 and 72 hrs by giemsa staining based light microscopic analysis2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1412954Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2018MedChemComm, Jun-01, Volume: 9, Issue:6
Evaluation of A-ring fused pyridine d-modified androstane derivatives for antiproliferative and aldo-keto reductase 1C3 inhibitory activity.
AID54196Percent inhibition of human placental Cytochrome P450 19A1 at 1:1 inhibitor: androstenedione (0.7 uM) ratio1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1256802Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells after 72 hrs by Annexin-V/FITC staining based flow cytometry (Rvb = 5.98%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID672713Inhibition of aromatase in human placental microsomes using [1beta-3H]androstenedione as substrate after 15 mins by liquid scintillation counting2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation.
AID1256783Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1193488Cell cycle arrest in human MCF7 cells assessed as cells accumulation at S phase at IC50 concentration after 48 hrs by flow cytometry (Rvb = 29.30%)2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID1270810Inhibition of human aromatase extracted from placental microsomes using [1beta-3H]androstenedione as substrate after 20 mins by radiometric assay2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID667432Cytotoxicity against human HT-29 cells after 1 hr by SRB assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives.
AID1256792Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2/M phase at IC50 concentration after 48 hrs by flow cytometry (Rvb = 7.5%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1256815Induction of apoptosis in human MDA-MB-231 cells assessed as degradation of nuclei after 48 and 72 hrs by giemsa staining based light microscopic analysis2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1192783Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
AID1193489Cell cycle arrest in human MCF7 cells assessed as cells accumulation at G2/M phase at IC50 concentration after 48 hrs by flow cytometry (Rvb =21.32 %)2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID53725Percent inhibition of human placental Cytochrome P450 19A1 at 3:1 inhibitor: androstenedione (0.7 uM) ratio1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives.
AID1270816Antitumor activity against NMU-induced mammary tumor in rat2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID1412955Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay2018MedChemComm, Jun-01, Volume: 9, Issue:6
Evaluation of A-ring fused pyridine d-modified androstane derivatives for antiproliferative and aldo-keto reductase 1C3 inhibitory activity.
AID1256810Induction of apoptosis in human MDA-MB-231 cells assessed as increase in BAX expression after 72 hrs by western blotting2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID667430Cytotoxicity against AR-negative human PC3 cells after 1 hr by SRB assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives.
AID667427Cytotoxicity against ER-positive human MCF7 cells after 1 hr by SRB assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives.
AID1693644Cytotoxicity activity against human MCF7 assessed as inhibition of cell growth measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.
AID1256794Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G0/G1 phase at IC50 concentration after 72 hrs by flow cytometry (Rvb = 54%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID53576Inhibition of 1 uM [1-beta-3H]-androstenedione binding to human placental microsome Cytochrome P450 19A11991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and biochemical studies of 16- or 19-substituted androst-4-enes as aromatase inhibitors.
AID1693649Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.
AID1270804Irreversible inhibition of human aromatase extracted from placental microsomes2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID1256779Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1256806Induction of apoptosis in human MDA-MB-231 cells assessed as increase in BAX expression after 48 hrs by western blotting2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID53739Binding affinity was measured on Cytochrome P450 19A11990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Mechanism and inhibition of cytochrome P-450 aromatase.
AID1193482Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID774133Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay2013Journal of natural products, Oct-25, Volume: 76, Issue:10
Synthesis and bioconversions of formestane.
AID53717Percent inhibition of human placental Cytochrome P450 19A1 at 1:1 inhibitor: androstenedione (0.7 uM) ratio1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives.
AID54197Percent inhibition of human placental Cytochrome P450 19A1 at 3:1 inhibitor: androstenedione (0.7 uM) ratio1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives.
AID704989Inhibition of human placental aromatase using [3H]-1beta-androstenedione as substrate after 16 hrs by [3H]-water method2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Novel aromatase inhibitors by structure-guided design.
AID53714Inhibition of Cytochrome P450 19A1 at the concentration of 1.5 uM1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and evaluation of 4-(substituted thio)-4-androstene-3,17-dione derivatives as potential aromatase inhibitors.
AID255351Percent inhibition at 2 uM against aromatase protein from human placental microsomes using [1-beta-3H]-androstenedione2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation.
AID1256799Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells after 48 hrs by Annexin-V/FITC staining based flow cytometry (Rvb = 2.9%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1256800Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells after 48 hrs by Annexin-V/FITC staining based flow cytometry (Rvb = 1.29%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID667431Cytotoxicity against human HeLa cells after 1 hr by SRB assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives.
AID1307751Inhibition of particulate fractions of human breast cancer derived aromatase2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.
AID1256809Induction of apoptosis in human MDA-MB-231 cells assessed as increase in cleaved PARP expression at IC50 concentration after 72 hrs by western blotting2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID159834Ratio of Kcat and KI for human placental microsome aromatase1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Interactions of thiol-containing androgens with human placental aromatase.
AID672712Inhibition of aromatase in human placental microsomes using [1beta-3H]androstenedione as substrate at 0.5 uM after 15 mins by liquid scintillation counting2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation.
AID53713Inhibition of Cytochrome P450 19A1 at the concentration of 0.75 uM1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and evaluation of 4-(substituted thio)-4-androstene-3,17-dione derivatives as potential aromatase inhibitors.
AID54043Evaluated for its competitive inhibitory activity against Cytochrome P450 19A1 with the use of human placental microsomal preparation1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and evaluation of 4-(substituted thio)-4-androstene-3,17-dione derivatives as potential aromatase inhibitors.
AID1057275Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
AID774132Inhibition of aromatase (unknown origin) using dibenzylfluorescein as substrate after 30 mins by fluorescence assay2013Journal of natural products, Oct-25, Volume: 76, Issue:10
Synthesis and bioconversions of formestane.
AID1057273Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
AID1193483Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID1192781Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
AID159833Binding affinity(KI) for formation of reversible enzyme-ligand complex with human placental aromatase (PL2)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Interactions of thiol-containing androgens with human placental aromatase.
AID1256797Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells after 48 hrs by Annexin-V/FITC staining based flow cytometry (Rvb = 90.39%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1057274Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1256793Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at SubG1 phase at IC50 concentration after 72 hrs by flow cytometry (Rvb = 1.9%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1192784Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1256819Induction of apoptosis in human MDA-MB-231 cells assessed as apoptotic cellular morphology after 72 hrs by giemsa staining based light microscopic analysis relative to control2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1412956Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2018MedChemComm, Jun-01, Volume: 9, Issue:6
Evaluation of A-ring fused pyridine d-modified androstane derivatives for antiproliferative and aldo-keto reductase 1C3 inhibitory activity.
AID1693645Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.
AID1256801Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells after 72 hrs by Annexin-V/FITC staining based flow cytometry (Rvb = 90.12%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1412957Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay2018MedChemComm, Jun-01, Volume: 9, Issue:6
Evaluation of A-ring fused pyridine d-modified androstane derivatives for antiproliferative and aldo-keto reductase 1C3 inhibitory activity.
AID1270846Inhibition of aromatase in denucleated ovarian fraction extracted from PMSG pretreated Wistar rat by using testosterone as substrate at 1 uM2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID1256784Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID364069Inhibition of aromatase in human placental microsomes assessed as tritiated water release after 15 mins using [1-beta, 3H]androstenedione as substrate by scintillation counting2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Evaluation of ursolic acid isolated from Ilex paraguariensis and derivatives on aromatase inhibition.
AID1193485Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID1256811Induction of apoptosis in human MDA-MB-231 cells assessed as decrease in Bcl-2 expression after 72 hrs by western blotting2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1193491Induction of apoptosis in human MCF7 cells assessed as apoptotic morphological changes at IC50 concentration after 48 hrs by light microscopy2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives.
AID1256788Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1693646Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.
AID1256781Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID1299176Inhibition of aromatase in human placental microsomes using [1beta-3H]-androstenedione as substrate assessed as tritiated H2O release at 0.5 uM after 15 mins by liquid scintillation counting method relative to control2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Exploring new chemical functionalities to improve aromatase inhibition of steroids.
AID1256804Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells after 72 hrs by Annexin-V/FITC staining based flow cytometry (Rvb = 1.14%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID159831Binding affinity constant for formation of reversible enzyme-ligand complex with human placental aromatase (PL1)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Interactions of thiol-containing androgens with human placental aromatase.
AID159828Maximum absorbance for formation of reversible-enzyme-ligand complexes with human placental aromatase (PL1)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Interactions of thiol-containing androgens with human placental aromatase.
AID1256795Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at IC50 concentration after 72 hrs by flow cytometry (Rvb = 33.7%)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1192782Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
AID25802kinact was determined.1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and evaluation of a new series of mechanism-based aromatase inhibitors.
AID1256782Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID1192780Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
AID1256780Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells.
AID667433Cytotoxicity against human MRC5 cells after 1 hr by SRB assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (364)

TimeframeStudies, This Drug (%)All Drugs %
pre-199083 (22.80)18.7374
1990's157 (43.13)18.2507
2000's59 (16.21)29.6817
2010's49 (13.46)24.3611
2020's16 (4.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.23 (24.57)
Research Supply Index6.05 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index57.86 (26.88)
Search Engine Supply Index2.09 (0.95)

This Compound (37.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials40 (10.44%)5.53%
Reviews60 (15.67%)6.00%
Case Studies4 (1.04%)4.05%
Observational0 (0.00%)0.25%
Other279 (72.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]